TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03662659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986213
Description: Relatlimab + Nivolumab specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin + capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin + capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin + leucovorin + fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin + leucovorin + fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Oxaliplatin + tegafur/gimeracil/oteracil potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: Oxaliplatin + tegafur/gimeracil/oteracil potassium
Study: NCT01581619

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Partial-Breast Irradiation
Description: 40 Gy in ten daily fractions over two weeks
Study: NCT01874938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Administered IV
Study: NCT04395287

Intervention type: BEHAVIORAL
Intervention: Leisure screen time
Description: Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
Study: NCT01427634

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Care
Description: Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Receive usual care as provided by the VAD clinical team.
Study: NCT01581008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Care to Alleviate Symptoms and Adjust to Illness
Description: A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychospiritual
Description: A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
Study: NCT00618605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 HIV-1 vaccine
Description: Recombinant adenovirus serotype 26 HIV-1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 HIV-1 vaccine
Description: Recombinant adenovirus serotype 26 HIV-1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 HIV-1 vaccine
Description: Recombinant adenovirus serotype 26 HIV-1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 HIV-1 vaccine
Description: Recombinant adenovirus serotype 26 HIV-1 vaccine
Study: NCT03774342

Intervention type: PROCEDURE
Intervention: Coronary Artery Bypass Grafting
Description: Patients undergoing coronary artery bypass grafting
Study: NCT01826435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Intervention
Description: Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
Study: NCT01716104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afalaza
Description: Safety and Efficacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safety and Efficacy
Study: NCT02739516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin
Description: In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
Study: NCT00535236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: 0.65 ml V212 in 4 dose regimen. Treatment period of 125 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
Study: NCT02447393

Intervention type: DRUG
Group type: OTHER
Intervention: levocetirizine
Description: levocetirizine

Intervention type: DRUG
Group type: OTHER
Intervention: cetirizine
Description: cetiridine

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo
Study: NCT04001699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative geriatric assessment
Description: In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative geriatric assessment
Description: In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
Study: NCT03164213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental: tDCS
Description: The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
Study: NCT02739516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH co-trigger
Description: In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
Study: NCT03624088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
Study: NCT02365571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
Study: NCT00663845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg Vardenafil taken orally 1h prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01147900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™-US formulation
Description: Intramuscular, single dose
Study: NCT03279328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin Barrier Moisturier
Description: Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
Study: NCT01729754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Description: Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
Study: NCT01283542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: 20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
Study: NCT02478580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuvigil
Description: Patients will receive Nuvigil before the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given before surgery
Study: NCT04516551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 allo-CAR-T cells
Description: The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
Study: NCT02791412

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention or coronary-artery bypass graft
Study: NCT03984487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surviving and Thriving in the Real World
Description: The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for the Education and Enrichment of Relational Skills
Description: PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
Study: NCT01365624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
Study: NCT05648682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salin
Description: Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey
Description: Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
Study: NCT01792518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5mg
Study: NCT03010020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCC
Description: Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Counseling
Description: GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
Study: NCT03233438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalbavancin
Description: Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
Study: NCT03057470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50% bolus insulin correction
Description: Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% bolus insulin correction
Description: Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150% bolus insulin correction
Description: Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0% bolus insulin correction
Description: Patients will receive no bolus insulin correction for post-exercise hyperglycemia
Study: NCT02702687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEF Feedback
Description: Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Feedback
Description: Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
Study: NCT04468074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy for Chronic Pain
Description: 1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises
Study: NCT02325297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter of condolence
Study: NCT03392870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative interventional programme
Description: The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: As usual
Description: The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
Study: NCT01951313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg consumption
Description: Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
Study: NCT03696095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)
Description: programmed intermittent bolus 5ml each one hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)
Description: continuous infusion 6ml/h
Study: NCT01469403

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks weight loss program, Cambridge.
Description: Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
Study: NCT00491608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin
Description: 1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
Study: NCT02367404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 60mg OD for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 60mg OD for 3 months
Study: NCT01729754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tildrakizumab Placebo
Description: Matching placebo to tildrakizumab administered SC
Study: NCT03164213

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy.
Study: NCT01729754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildrakizumab Placebo
Description: Matching placebo to tildrakizumab administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept Placebo
Description: Matching placebo to etanercept administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept Placebo
Description: Matching placebo to etanercept administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept Placebo
Description: Matching placebo to etanercept administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept 50 mg
Description: Etanercept 50 mg administered SC
Study: NCT00503308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abbreviated HIV test counseling
Description: abbreviated HIV pre-test counseling